Yes, biological therapies (biologics) are available on the NHS for individuals with severe psoriasis who have not responded to other treatments. Biologics represent a significant advancement in dermatology because they are highly targeted, specifically engineered to block the proteins in the immune system, such as TNF-alpha or Interleukin-17, that drive the inflammatory process of psoriasis. Because these treatments are expensive and require specialist monitoring, they are subject to strict clinical criteria defined by the National Institute for Health and Care Excellence (NICE).
What We’ll Discuss in This Article
- The clinical criteria for accessing biologics on the NHS.
- The role of the PASI and DLQI scores in the referral process.
- Different types of biologics and how they are administered.
- The requirement for “failed” systemic treatments.
- Potential side effects and long-term monitoring.
- How to discuss a biological referral with your dermatologist.
NICE criteria for biologic eligibility
In the UK, biologics are not offered as a first-line or second-line treatment. To be considered for a biologic on the NHS, a patient must meet specific clinical thresholds:
- Severity of Disease: The psoriasis must be classified as severe. This is typically defined as having a PASI score of 10 or more and a DLQI score of more than 10.
- Treatment Failure: The patient must have tried and failed at least two standard systemic treatments (such as methotrexate, ciclosporin, or acitretin), or have a medical reason why they cannot take those medications.
- Phototherapy: The patient must have also failed, or be unable to receive, phototherapy (UV light treatment).
How biologics differ from traditional treatments
Unlike traditional systemic pills that affect the entire immune system, biologics are “targeted” therapies. They are made from living cells and are designed to bind to specific molecules that cause the rapid skin cell growth in psoriasis.
- TNF-alpha Inhibitors: These target a protein called tumour necrosis factor (e.g., Adalimumab, Etanercept).
- IL-17 and IL-23 Inhibitors: These target newer pathways that are highly specific to psoriasis (e.g., Secukinumab, Ustekinumab, Risankizumab).
Administration and monitoring
Biologics are usually administered as injections under the skin (subcutaneous) or occasionally via an intravenous (IV) drip in a hospital setting. Most patients are taught how to self-inject at home, similar to an insulin pen. Because these medications influence the immune system, the NHS requires rigorous safety monitoring:
- Pre-treatment Screening: You will be tested for tuberculosis (TB), hepatitis, and other latent infections before starting.
- Regular Blood Tests: To monitor your immune response and overall organ function.
- Review Cycles: Your dermatologist will review the effectiveness of the biologic at set intervals (usually at 12 to 16 weeks). If the PASI score hasn’t dropped by 75% or more, the medication may be considered ineffective and a different biologic may be trialled.
Accessing biologics in the UK
The journey to biological therapy always begins in secondary care. A GP cannot initiate these treatments; you must be under the care of a hospital consultant dermatologist. If you feel your current systemic treatment is not working or the side effects are too severe, you should request a specialist review to discuss your eligibility for biologics. The NHS provides these treatments through specialist clinics that have the resources to manage high-cost drugs and the necessary nursing support for patient training.
Conclusion
Biological therapies have transformed the lives of many people with severe psoriasis in the UK, often leading to near-total skin clearance. While the NICE criteria for accessing them are strict, they ensure that these powerful medications are reserved for those with the greatest clinical need. By understanding the scoring systems (PASI and DLQI) and working closely with a dermatology team, patients with severe psoriasis can access advanced treatments that offer a high probability of long-term remission.
Are biologics a permanent cure?
No; there is currently no cure for psoriasis. Biologics manage the condition very effectively, but symptoms may return if the treatment is stopped.
What are biosimilars?
A biosimilar is a medication that is highly similar to an original biologic. The NHS often uses biosimilars (like Adalimumab biosimilars) because they are more cost-effective while offering the same clinical benefits.
Can I take biologics if I want to have a baby?
Some biologics are considered safer than others during pregnancy and breastfeeding; you must discuss your family planning with your dermatologist.
What is the most common side effect?
The most common side effects are mild reactions at the injection site (redness or itching) and a slightly increased risk of minor infections like colds or sinus issues.
How long do I have to wait to see if it works?
Most patients see a significant improvement within the first 4 to 12 weeks, though some of the newer IL-17 and IL-23 inhibitors can show results even faster.
Do I have to pay for biologics on the NHS?
Like other NHS hospital-prescribed medications, these are provided at no cost to the patient beyond the standard prescription charge (if applicable).
Can biologics help my psoriatic arthritis too?
Yes; many biologics are licensed to treat both the skin plaques of psoriasis and the joint inflammation of psoriatic arthritis simultaneously.
Authority Snapshot (E-E-A-T Block)
This article examines the clinical availability and criteria for biological therapies on the NHS. It is written by the MyPatientAdvice Medical Writing/Research Team and reviewed by Dr. Rebecca Fernandez, a UK-trained physician with experience in internal medicine, dermatology, and acute care. All information is strictly aligned with the clinical standards and technology appraisals provided by the NHS and NICE for 2026.
